RxDoctor Payments Data

Robert Sprung, MD

Cardiology · Farmington, NMNPI 1255314837

Payments from drug & device makers

$1,216in general payments, 2019–2025

Across 64 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$411
  • Johnson & Johnson$141
  • AstraZeneca$108
  • Novartis$108
  • Viatris Specialty LLC$107
  • Amgen$72
  • plus $270 from 8 others

What the payments were for

  • Food & beverage$1,17997%
  • Education$373%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few cardiology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$181,045
Medicare patients
263
Services billed
2,525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab112$119,436
EliquisApixaban90$114,161
OzempicSemaglutide74$102,091
XareltoRivaroxaban70$72,311
JardianceEmpagliflozin48$69,408
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$56,308
FarxigaDapagliflozin Propanediol45$55,322
EntrestoSacubitril/Valsartan34$52,549
RybelsusSemaglutide26$39,084
Praluent PenAlirocumab39$37,580
JanuviaSitagliptin Phosphate37$28,467
SymbicortBudesonide/Formoterol Fumarate50$18,741
VascepaIcosapent Ethyl33$18,374
TrulicityDulaglutide15$17,092
MultaqDronedarone Hcl14$16,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$17$141,175100 claims
PfizerEliquis$35$114,16190 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$108$88,132114 claims
Johnson & JohnsonXarelto$141$72,31170 claims
Boehringer IngelheimJardiance$37$69,40848 claims
GSKTrelegy Ellipta$60$56,30837 claims
NovartisEntresto$108$52,54934 claims
MerckJanuvia, Janumet$56$38,65250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in New Mexicoon file to place this against a meaningful peer group, so we don't.

Other cardiology in Farmington

Where these figures come from

Is this you, or does something look wrong? →